Evidence for
better drugs
We use AI and population scale data to provide predictive evidence on clinical efficacy. We de-risk development and increase the likelihood of success.
.svg){kind=icon}
Evidence for
Yet, we still cannot answer the most basic medical questions for the vast majority of diseases: who gets sick in the first place? What characterizes people once they are diagnosed? Who continues to get complications? These answers are necessary to develop safe and effective drugs. We integrate billions of data points of human-centric data to provide answers in silico and at scale. Our platform generates actionable evidence to de-risk development and increase the likelihood of success.
Identify the effective targets with evidence from thousands of subclinical phenotypes and natural genetic experiments.
Validate established targets across thousands of subclinical phenotypes and clinical endpoints in silico, before investing in clinical trials.
Inform clinical development with powerful biomarkers to stratify patient populations, validate MoA hypotheses and select the right patients.
Identify high risk individuals with subclinical phenotypes to prognostically enrich clinical trials reducing failure risk and cost.
.svg)
Predictive evidence.
Reduced failure risk.